Scleroderma (Systemic Sclerosis) – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)

Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud’s phenomenon and, often, painful digital ulcers. Risks of pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis are higher in SSc patients than in the general population and underlie a high mortality rate. A complex array of treatments may be used in the management of SSC; systemic immunosuppressants are prescribed to treat ILD and skin fibrosis, while other symptoms (e.g., PAH, vasculopathy, renal crisis) are treated with varying combinations of calcium channel blockers, endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, ACE inhibitors, and off-label biologics. This content provides context for emerging players seeking to capitalize on the unmet needs in this underserved arena.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SSc patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SSc patients?
  • How has Ofev been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of SSc patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of SSc patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geography: United States.

Real-world data: Longitudinal patient-level claims data analysis.

Key drugs covered: Ofev, Esbriet, Rituxan, Adempas, calcium channel blockers, conventional oral immunosuppressants, corticosteroids, PDE-5 inhibitors, select biologics.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Scleroderma (Systemic Sclerosis) - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms CDA Scleroderma (Systemic Sclerosis) US June 2021
    • Treatment Algorithms CDA Scleroderma (Systemic Sclerosis) US 2021 Dashboard

launch Related Market Assessment Reports